We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Modulation of Redox Environment Increases Breast Cancer Aggressiveness

By Gerald M. Slutzky, PhD
Posted on 16 Nov 2016
Cancer researchers have identified an enzyme that promotes the transition of breast tissue from epithelial (non-cancerous) to mesenchymal (metastatic cancer-like) modes during the development of invasive triple negative breast cancer.

Since analysis of breast cancers in The Cancer Genome Atlas database had revealed strong positive correlation between a tumor's EMT (epithelial - mesenchymal transition) score and the expression of the manganese superoxide dismutase (MnSOD) enzyme, investigators at the National University of Singapore (Singapore) sought to assess the involvement of MnSOD during the switch between epithelial-like and mesenchymal-like phenotypes in breast carcinomas.

As a member of the iron/manganese superoxide dismutase family, this enzyme transforms toxic superoxide, a byproduct of the mitochondrial electron transport chain, into hydrogen peroxide and diatomic oxygen. More...
This function allows SOD2 to clear mitochondrial reactive oxygen species (ROS) and, as a result, confer protection against cell death. As a result, this protein plays an anti-apoptotic and pro-carcinogenic role against oxidative stress, ionizing radiation, and inflammatory cytokines.

The investigators reported in the August 2016 issue of the journal Antioxidants & Redox Signaling that they had observed the overexpression of MnSOD in mesenchymal-like breast cancers that exhibited increased migratory, invasive, and metastatic capacities. On the other hand, repression of MnSOD induced an epithelial phenotype with a reduction in EMT markers and cells' scattering, invasive, and motile capacity.

The positive correlation between MnSOD and EMT score was significant and consistent across all breast cancer subtypes. Similarly, a positive correlation of EMT score and MnSOD expression was observed in established cell lines derived from breast cancers exhibiting phenotypes ranging from the most epithelial to the most mesenchymal.

The investigators proposed that at the mechanistic level MnSOD appeared to drive epithelial to mesenchymal transition via its ability to modulate the cellular redox environment by adjusting the ratio of superoxide to hydrogen peroxide.

"By suppressing MnSOD expression or its activity in triple negative breast cancer patients, we are able to make the tumor cells less aggressive and more sensitive to chemotherapy," said senior author Dr. Alan Prem Kumar, principal associate in the Cancer Science Institute of Singapore at the National University of Singapore.

Related Links:
National University of Singapore


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.